Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

A. Lynn Patterson, Richard E. Greenberg, Lamar Weems, Robert R. Bahnson, Zev Wajsman, Mervyn Israel, Trevor Sweatman, Denise Webber, Joseph Gulfo

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Objectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT. Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly.Results. The use of valrubicin after TURBT was generally well tolerated. Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77%), hematuria (59%), and urgency/frequency (23%). Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall.Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)232-235
Number of pages4
JournalUrology
Volume56
Issue number2
DOIs
StatePublished - Aug 2000

Keywords

  • Administration, Intravesical
  • Aged
  • Carcinoma in Situ/drug therapy
  • Combined Modality Therapy
  • Doxorubicin/administration & dosage
  • Drug Administration Schedule
  • Humans
  • Male
  • Pilot Projects
  • Postoperative Complications/diagnosis
  • Salvage Therapy
  • Treatment Outcome
  • Urinary Bladder Neoplasms/drug therapy
  • Urinary Bladder/surgery
  • Urination Disorders/diagnosis

Fingerprint

Dive into the research topics of 'Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer'. Together they form a unique fingerprint.

Cite this